BGB-3245
Mapkure,Beigene,springworks
['bgb-3245', 'bgb-324', 'solid tumor', 'springworks']
updated clinical data from the phase 1a/1b study evaluating bgb-3245, an investigational, selective raf dimer inhibitor, in adult patients w/ advanced or refractory solid tumors harboring mapk pathway aberrations presented today at #aacr23. learn more: 
At SpringWorks, we bring tenacity to work every day because patients need answers now.